Tag: M.W:500-600

Let¡¯s face it, organic chemistry can seem difficult to learn. Especially from a beginner¡¯s point of view. Like 137076-54-1, Name is 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid. In a document type is Article, introducing its new discovery., 137076-54-1

Methoxinine ? an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates

Radiolabelled peptides with high specificity and affinity towards receptors that are overexpressed by tumour cells are used in nuclear medicine for the diagnosis (imaging) and therapy of cancer. In some cases, the sequences of peptides under investigations contain methionine (Met), an amino acid prone to oxidation during radiolabelling procedures. The formation of oxidative side products can affect the purity of the final radiopharmaceutical product and/or impair its specificity and affinity towards the corresponding receptor. The replacement of Met with oxidation resistant amino acid analogues, for example, norleucine (Nle), can provide a solution. While this approach has been applied successfully to different radiolabelled peptides, a Met ? Nle switch only preserves the length of the amino acid side chain important for hydrophobic interactions but not its hydrogen-bonding properties. We report here the use of methoxinine (Mox), a non-canonical amino acid that resembles more closely the electronic properties of Met in comparison to Nle. Specifically, we replaced Met15 by Mox15 and Nle15 in the binding sequence of a radiometal-labelled human gastrin derivative [d-Glu10]HG(10-17), named MG11 (d-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2). A comparison of the physicochemical properties of 177Lu-DOTA[X15]MG11 (X = Met, Nle, Mox) in vitro (cell internalization/externalization properties, receptor affinity (IC50), blood plasma stability and logD) showed that Mox indeed represents a suitable, oxidation-stable amino acid substitute of Met in radiolabelled peptide conjugates. Copyright

Interested yet? Keep reading other articles of 142128-92-5!, 137076-54-1

Reference£º
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI

52093-25-1, Because a catalyst decreases the height of the energy barrier, its presence increases the reaction rates of both the forward and the reverse reactions by the same amount.52093-25-1, Name is Europium(III) trifluoromethanesulfonate, molecular formula is C3EuF9O9S3. In a article£¬once mentioned of 52093-25-1

Lanthanide(III) triflates as recyclable catalysts for atom economic aromatic nitration

Lanthanide(III) triflates catalyse (1-10 mol%) the nitration of a range of simple aromatic compounds in good to excellent yield using stoichiometric quantities of 69% nitric acid; the only by-product is water and the catalyst can be readily recycled by simple evaporation.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.52093-25-1. In my other articles, you can also check out more blogs about 52093-25-1

Reference£º
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Chemistry is the experimental and theoretical study of materials on their properties at both the macroscopic and microscopic levels.In a patent£¬ 52093-25-1, Which mentioned a new discovery about 52093-25-1

COMPOUNDS USEFUL AS LIGANDS AND PARTICULARLY AS ORGANIC CHROMOPHORES FOR COMPLEXING LANTHANIDES AND APPLICATIONS THEREOF

The invention relates to the use of compounds comprising at least one 2-(1H-tetrazol-5-yl)pyridine unit, of formula (I) below: as ligands for lanthanides and, more especially, as organic chromophores for complexing these elements. It also relates to lanthanide complexes using these compounds as complexing organic chromophores, and to new compounds containing one or more 2-(1H-tetrazol-5-yl)pyridine units, which are useful as ligands for lanthanides and, in particular, as organic chromophores for complexing these elements. Applications: photonics and optoelectronics, especially for forming light-emitting devices such as electroluminescent diodes; biology, as for example for the preparation of luminescent probes.

Because enzymes can increase reaction rates by enormous factors and tend to be very specific, 52093-25-1, typically producing only a single product in quantitative yield, they are the focus of active research.you can also check out more blogs about 52093-25-1

Reference£º
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1351279-73-6, Because a catalyst decreases the height of the energy barrier, its presence increases the reaction rates of both the forward and the reverse reactions by the same amount.1351279-73-6, Name is 4,4′,4”,4”’-(Ethene-1,1,2,2-tetrayl)tetrabenzoic acid, molecular formula is C30H20O8. In a article£¬once mentioned of 1351279-73-6

Sensing and capture of toxic and hazardous gases and vapors by metal-organic frameworks

Toxic and hazardous chemical species are ubiquitous, predominantly emitted by anthropogenic activities, and pose serious risks to human health and the environment. Thus, the sensing and subsequent capture of these chemicals, especially in the gas or vapor phase, are of extreme importance. To this end, metal-organic frameworks have attracted significant interest, as their high porosity and wide tunability make them ideal for both applications. These tailorable framework materials are particularly promising for the specific sensing and capture of targeted chemicals, as they can be designed to fit a diverse range of required conditions. This review will discuss the advantages of metal-organic frameworks in the sensing and capture of harmful gases and vapors, as well as principles and strategies guiding the design of these materials. Recent progress in the luminescent detection of aromatic and aliphatic volatile organic compounds, toxic gases, and chemical warfare agents will be summarized, and the adsorptive removal of fluorocarbons/chlorofluorocarbons, volatile radioactive species, toxic industrial gases and chemical warfare agents will be discussed.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.1351279-73-6. In my other articles, you can also check out more blogs about 1351279-73-6

Reference£º
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI

Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In some cases, the catalyzed mechanism may include additional steps.In a article, 76089-77-5, molcular formula is C3CeF9O9S3, introducing its new discovery. 76089-77-5

POLYDENTATE LIGAND METAL COMPLEX

The present invention provides a metal complex that has excellent durability, and a device and the like having excellent durability that uses such a metal complex. Specifically, the present invention provides a metal complex comprising (a) a polydentate ligand having denticity of five or more that includes a heteroaromatic ring which contains two or more atoms selected from the group consisting of a nitrogen atom, an oxygen atom, and a sulfur atom, and (b) an ion of a metal selected from the group consisting of cerium, praseodymium, ytterbium, and lutetium; a composition comprising the metal complex and a charge transport material; an organic thin film obtained by using the metal complex or composition; and a device obtained by using the metal complex, composition, or organic thin film.

One of the oldest and most widely used commercial enzyme inhibitors is aspirin, 76089-77-5, which selectively inhibits one of the enzymes involved in the synthesis of molecules that trigger inflammation. you can also check out more blogs about 76089-77-5

Reference£º
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI

52093-25-1, Catalysts are substances that increase the reaction rate of a chemical reaction without being consumed in the process. 52093-25-1, Name is Europium(III) trifluoromethanesulfonate, molecular formula is C3EuF9O9S3. In a Article, authors is Nwe, Kido£¬once mentioned of 52093-25-1

Tethered dinuclear europium(III) macrocyclic catalysts for the cleavage of RNA

Dinuclear europium(III) complexes of the macrocycles 1,3-bis[1-(4,7,10- tris(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane]-m-xylene (1), 1,4-bis[1-(4,7,10-tris(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane] -p-xylene (2), and mononuclear europium(III) complexes of macrocycles 1-methyl-,4,7,10-tris(carbamoylmethyl)-1,4,7,10-tetraazacyclododecane (3), 1-[3?-(N,N-diethylaminomethyl)benzyl]-4,7,10-tris(carbamoylmethyl)-1,4,7, 10-tetraazacyclododecane (4), and 1,4,7-tris(carbamoylmethyl)-1,4,7,10- tetraazacyclododecane (5) were prepared. Studies using direct excitation ( 7F0 ? 5D0) europium(III) luminescence spectroscopy show that each Eu(III) center in the mononuclear and dinuclear complexes has two water ligands at pH 7.0, I = 0.10 M (NaNO 3) and that there are no water ligand ionizations over the pH range of 7-9. All complexes promote cleavage of the RNA analogue 2-hydroxypropyl-4- nitrophenyl phosphate (HpPNP) at 25C (I = 0.10 M (NaNO3), 20 mM buffer). Second-order rate constants for the cleavage of HpPNP by the catalysts increase linearly with pH in the pH range of 7-9. The second-order rate constant for HpPNP cleavage by the dinuclear Eu(III) complex (Eu2(1)) at pH 7 is 200 and 23-fold higher than that of Eu(5) and Eu(3), respectively, but only 7-fold higher than the mononuclear complex with an aryl pendent group, Eu(4). This shows that the macrocycle substituent modulates the efficiency of the Eu(III) catalysts. Eu2(1) promotes cleavage of a dinucleoside, uridylyl-3?,5?-uridine (UpU) with a second-order rate constant at pH 7.6 (0.021 M-1 s-1) that is 46-fold higher than that of the mononuclear Eu(5) complex. Methyl phosphate binding to the Eu(III) complexes is energetically most favorable for the best catalysts, and this supports an important role for the catalyst in stabilization of the developing negative charge on the phosphorane transition state. Despite the formation of a bridging phosphate ester between the two Eu(III) centers in Eu2(1) as shown by luminescence spectroscopy, the two metal ion centers are only weakly cooperative in cleavage of RNA and RNA analogues.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. 52093-25-1, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 52093-25-1, in my other articles.

Reference£º
Metal catalyst and ligand design,
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

To a solution of tri-Boc cyclam S7 (3.80 g, 7.59 mmol) in anhydrous CH3CN (160 mL) were added Na2CO3 (0.956 g, 9.10 mmol) and ethyl bromoacetate (1.00 mL, 9.02 mmol). The reaction mixture was stirred at reflux under Ar overnight. The insoluble salts were filtered, and the filtrate was concentrated under reduced pressure. The residuewas purified by flash column chromatography (silica gel, EtOAc:hexane = 1:2 rampingto 1:1) to give S9 as a white foam (4.06 g, 91%). RF (EtOAc:hexane = 1:1) 0.67. IRvmax/cm 2974, 2933, 2869, 1737, 1685, 1465, 1411, 1366, 1292, 1240, 1154, 1032,772, 731. 1H NMR (300 MHz, CDCI3) 5 1.26 (t, 3H, J 7.2, COOCH2CH3), 1 .46 (5, 27H, 3 C(CH3)3), 1.60-1.78 (m, 2H, CH2CH2CH2), 1.85-2.00 (m, 2H, CH2CH2CH2), 2.60-2.72(m, 2H, CH2N(CH2COOCH2CH3)CH2), 2.80-2.90 (m, 2H, CH2N(CH2COOCH2CH3)CH2),3.22-3.65 (m, 14H, 3 x CH2N(Boc)CH2 & NCH2COOCH2CH3), 4.14 (q, 2H, J 7.2, COOCH2CH3). ?3C NMR (75 MHz, CDCI3) 5 14.2, 27.0, 28.4, 45.2, 46.8, 47.1, 47.3,48.3, 51.8, 52.9, 53.6, 55.3, 60.1, 79.4, 155.4, 155.6, 170.9 (twelve carbon signals overlapping or obscured). MS (ESI) m/z 587.0 ([M+H], 6%), 609.1 ([M+Na], 100%), 1194.9 ([2M+Na], 47%). The spectroscopic data were in agreement with those in the literature.27?28, 170161-27-0

The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; THE UNIVERSITY OF SYDNEY; RUTLEDGE, Peter; TODD, Matthew; TRICCAS, James Anthony; WO2014/153624; (2014); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

General procedure: An excess of anhydrous K2CO3 was added to a solution of di- or triprotected cyclam (1 mmol) in dry CH3CN (50 mL) and then a solution of 2,2′-bis(bromomethyl) biphenyl (1 or 2 mmol) in the same solvent was added. The suspension was kept at reflux with strong stirring for 3-4 days. The resulting mixture was filtered and the solvent was vacuum distilled to give a residue that was purified by column chromatography over silica with CH2Cl2/MeOH as the eluent., 170161-27-0

170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Burguete, M. Isabel; Clares, M. Paz; Garcia-Espana, Enrique; Luis, Santiago V.; Querol, Manel; Marti-Centelles, Vicente; Tetrahedron; vol. 67; 25; (2011); p. 4655 – 4663;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

137076-54-1, 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of DOTA tri-t-butyl ester (10 mg, 0.017 mmol), HBTU (7.8 mg, 0.021 mmol) and DIEA (6.0 muL, 0.034 mmol) in anhydrous DMF (0.5 mL) was stirred at room temperature under nitrogen for 20 minutes, and treated with the product of Part A (8.7 mg, 0.017 mmol). Stirring was continued for 1 hour and the solution was concentrated under reduced pressure. The residue was dissolved in TFA (1 mL), treated with TIS (10 muL), and stirred for 4 hours. The solution was concentrated under reduced pressure and the residue was purified by HPLC on a Phenomenex Luna C18 column (21.2 x 250 mm) using a 0.9%/min gradient of 0 to 18% acetonitrile containing 0.1% TFA at a flow rate of 20 mL/min. The main EPO product peak eluting at 20.5 minutes was lyophilized to give the title compound as a colorless solid (8.5 mg, 62%, HPLC purity 96%). MS (ESI): 793.5 (40, M+H), 396.9 (100, M+2H); HRMS: Calcd for C37H62N9O10 (M+H): 792.4620; Found: 792.462

137076-54-1, The synthetic route of 137076-54-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BRISTOL-MYERS SQUIBB PHARMA COMPANY; WO2007/5491; (2007); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: The y-carbaldehyde intermediates (29.0 muL, 500 mumol) were added to a solution of tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (35.7 mg, 71.0 mumol) in MeOH (1.0 mL) and AcOH (100 L) under N2 and stirred for 2 h at room temperature. NaBH3CN (8.90 mg, 142 mumol) was added slowly to the reaction mixture and stirred at room temperature for 24 h. The reaction mixture was poured into saturated NaHCO3, extracted with EtOAc and dried with MgSO4. The organic layer was then washed with water and brine, dried with MgSO4 and concentrated under reduced pressure to obtain the corresponding tri-N-Boc-protected amine intermediates (68.9 mg), which were used in the next step without purification. The intermediates were then dissolved in CHCl3 (2.50 mL) and treated with 95% aqueous TFA (2.50 mL) at 0 C for 6 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC to obtain the desired compounds 6-12.

170161-27-0, The synthetic route of 170161-27-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Sakyiamah, Maxwell M.; Kobayakawa, Takuya; Fujino, Masayuki; Konno, Makoto; Narumi, Tetsuo; Tanaka, Tomohiro; Nomura, Wataru; Yamamoto, Naoki; Murakami, Tsutomu; Tamamura, Hirokazu; Bioorganic and Medicinal Chemistry; vol. 27; 6; (2019); p. 1130 – 1138;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI